Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Citi’s 11th Annual Biotech Conference September 7 in Boston
Robert W. Baird & Co. 2016 Global Healthcare Conference September 8 in New York
Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology September 28 in New York
SAN RAFAEL, Calif., Aug. 31, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that management will participate in the Gene Therapy Panel at Citi’s 11th Annual Biotech Conference on September 7, 2016 at 1:00pm ET in Boston, the Robert W. Baird & Co. 2016 Global Healthcare Conference September 8, 2016 at 9:40am ET in New York and the Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology on September 28, 2016 at 10:00am ET in New York. To access the live webcasts, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following the event.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
